Albert Cha

Albert Cha, MD, PhD., has served as a member of KalVista’s Board of Directors since the consummation of the Carbylan Therapeutics, Inc. transaction in 2016. Dr. Cha served as a member of the Carbylan Board of Directors starting in November 2007. He is currently a Managing Partner with Frazier Life Sciences. Dr. Cha was previously a Managing Partner at Vivo Capital, a healthcare investment firm. Dr. Cha currently serves as chairman of the Board of Directors of Ascendis Pharma A/S (NASDAQ: ASND). During the past five years, he also served as a member of the Boards of Directors of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Sierra Oncology, Inc. (NASDAQ: SRRA). Dr. Cha received a BS and an MS from Stanford University and an MD and a Ph.D. from the University of California, Los Angeles.